---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-280196"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:30:00.953410+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ORIC Pharma Q3 2025: $413M cash; ORIC-944 dose exploration complete with positive data

## Summary
- Cash and investments of $413M as of Sep 30, 2025; expected to fund operating plan into 2H 2028.
- R&D expenses Q3 2025: $28.8M (down $2.4M YoY); G&A expenses: $7.9M (up $0.8M YoY).
- ORIC-944 Phase 1b dose exploration completed; PSA50 in 55% (11/20), PSA90 in 20% (4/20), ctDNA clearance in 59% (10/17) mCRPC patients.
- Provisional RP2Ds selected for ORIC-944 with darolutamide (400mg/600mg QD) and apalutamide (600mg/800mg/1200mg QD).
- Appointed Kevin Brodbeck, PhD as Chief Technical Officer; enozertinib data expected at ESMO Asia Dec 2025.

## SEC filing metadata
- accession: 0001193125-25-280196
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312525280196/0001193125-25-280196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312525280196/oric-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-280196
- JSON: https://secwatch.observer/filing/0001193125-25-280196.json
- Plain text: https://secwatch.observer/filing/0001193125-25-280196.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.